History of the use of HPV testing in cervical screening and in the management of abnormal cervical screening results

被引:57
作者
Cox, J. Thomas [1 ,2 ]
机构
[1] Univ Calif Santa Barbara, ASCCP, Santa Barbara, CA 93106 USA
[2] Univ Calif Santa Barbara, Womens Clin, Student Hlth Serv, Santa Barbara, CA 93106 USA
关键词
Human papillomavirus (HPV); testing; Papanicolaou (Pap) test; cotesting; hybrid capture; polymerase chain reaction (PCR); Invader HPV; HPV mRNA; p16; HUMAN-PAPILLOMAVIRUS DNA; ATYPICAL SQUAMOUS-CELLS; HIGH-RISK HPV; MESSENGER-RNA; FOLLOW-UP; UNDETERMINED SIGNIFICANCE; INTRAEPITHELIAL LESIONS; COST-EFFECTIVENESS; WOMEN; CANCER;
D O I
10.1016/S1386-6532(09)70002-2
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Twenty years have passed since the first studies using human papillomavirus (HPV) testing began in clinical settings. At that time controversy regarding the role of HPV in cervical carcinogenesis still divided the scientific world. Epidemiological and natural history studies on HPV and cervical cancer in the ensuing two decades secured the necessary role of high-risk (carcinogenic) HPV in the genesis of cervical cancer, providing the rationale for testing for its cause. Subsequently, cross sectional studies and large randomized trials have provided clinical validation for high-risk HPV testing in triage of atypical squamous cells of undetermined significance (ASC-US), in postcolposcopy management of women referred for ASC-US, atypical squamous cells "cannot rule out high grade" (ASC-H), atypical glandular cells "not otherwise specified" (AGC NOS) and low grade squamous intraepithelial lesion (LSIL) and not found to have cervical. intraepithelial neoplasia (CIN) 2+ or adenocarcinoma in situ (AIS) at initial colposcopy, in post-treatment of CIN 2+ surveillance, and in cotesting with the Papanicolaou (Pap) test of women age 30 and over. This is the story of the road traveled that brought the clinical use of HPV testing from its genesis only a few years after Dr. zur Hausen's discovery to its present eminent role in both primary cervical cancer screening and abnormal Pap management. (C) 2009 Elsevier B.V. All rights reserved.
引用
收藏
页码:S3 / S12
页数:10
相关论文
共 58 条
[1]   Clinical utility of HPV-DNA detection: Triage of minor cervical lesions, follow-up of women treated for high-grade CIN: An update of pooled evidence [J].
Arbyn, M ;
Paraskevaidis, E ;
Martin-Hirsch, P ;
Prendiville, W ;
Dillner, J .
GYNECOLOGIC ONCOLOGY, 2005, 99 (03) :S7-S11
[2]   Virologic versus cytologic triage of women with equivocal pap smears: A meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia [J].
Arbyn, M ;
Buntinx, F ;
Van Ranst, M ;
Paraskevaidis, E ;
Martin-Hirsch, P ;
Dillner, J .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (04) :280-293
[3]   A NEW TYPE OF PAPILLOMAVIRUS DNA, ITS PRESENCE IN GENITAL CANCER BIOPSIES AND IN CELL-LINES DERIVED FROM CERVICAL-CANCER [J].
BOSHART, M ;
GISSMANN, L ;
IKENBERG, H ;
KLEINHEINZ, A ;
SCHEURLEN, W ;
HAUSEN, HZ .
EMBO JOURNAL, 1984, 3 (05) :1151-1157
[4]   Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial [J].
Carozzi, Francesca ;
Confortini, Massimo ;
Dalla Palma, Paolo ;
Del Mistro, Annarosa ;
Gillio-Tos, Anna ;
De Marco, Laura ;
Giorgi-Rossi, Paolo ;
Pontenani, Giovanni ;
Rosso, Stefano ;
Sani, Cristina ;
Sintoni, Catia ;
Segnan, Nereo ;
Zorzi, Manuel ;
Cuzick, Jack ;
Rizzolo, Raffaella ;
Ronco, Guglielmo .
LANCET ONCOLOGY, 2008, 9 (10) :937-945
[5]   Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities [J].
Castle, PE ;
Solomon, D ;
Schiffman, M ;
Wheeler, CM .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (14) :1066-1071
[6]   A cross-sectional study of a prototype carcinogenic human papillomavirus E6/E7 messenger RNA assay for detection of cervical precancer and cancer [J].
Castle, Philip E. ;
Dockter, Janel ;
Giachetti, Cristina ;
Garcia, Francisco A. R. ;
McCormick, Mary Kay ;
Mitchell, Amy L. ;
Holladay, E. Blair ;
Kolk, Daniel P. .
CLINICAL CANCER RESEARCH, 2007, 13 (09) :2599-2605
[7]   Five-Year Experience of Human Papillomavirus DNA and Papanicolaou Test Cotesting [J].
Castle, Philip E. ;
Fetterman, Barbara ;
Poitras, Nanty ;
Lorey, Yhomas ;
Shaber, Ruth ;
Kinney, Walter .
OBSTETRICS AND GYNECOLOGY, 2009, 113 (03) :595-600
[8]   Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy [J].
Cox, JT ;
Schiffman, M ;
Solomon, D .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2003, 188 (06) :1406-1412
[9]  
COX JT, 1992, OBSTET GYNECOL, V80, P389
[10]   Evaluating the role of HPV testing for women with equivocal Papanicolaou test findings [J].
Cox, JT .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (17) :1645-1647